ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition

Rationale: The mitogen-activated protein kinase pathway (MAPK) is one of the major cancer-driving pathways found in non-small cell lung cancer (NSCLC) patients. ERK inhibitors (ERKi) have been shown to be effective in NSCLC patients with MAPK pathway mutations. However, like other MAPK inhibitors, E...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Shurui, Li, Na, Bai, Xuetao, Liu, Lu, Banerjee, Ananya, Lavudi, Kousalya, Zhang, Xiaoli, Zhao, Jihe, Venere, Monica, Duan, Wenrui, Zhang, Junran, Welliver, Meng X., He, Kai, Wang, Qi-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576621/
https://www.ncbi.nlm.nih.gov/pubmed/36276640
http://dx.doi.org/10.7150/thno.73099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576621/
https://www.ncbi.nlm.nih.gov/pubmed/36276640
http://dx.doi.org/10.7150/thno.73099

Ejemplares similares